Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies

Article Pharmacology & Pharmacy

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Weijia Li et al.

Summary: The use of SGLT2is is associated with a reduced incidence of heart failure hospitalization and acute kidney injury in patients with HFpEF and T2DM.

DRUGS-REAL WORLD OUTCOMES (2022)

Add to Collection

Article Endocrinology & Metabolism

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

Alison K. K. Wright et al.

Summary: This study assessed the associations between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists with risk for major adverse cardiac and cerebrovascular events (MACCE) and heart failure (HF) in people with type 2 diabetes. The results showed that SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in the prevention of MACCE and HF, while GLP-1RA may be beneficial for HF.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease

Jinnie J. Rhee et al.

Summary: In patients with type 2 diabetes and chronic kidney disease, the use of SGLT-2 inhibitors compared to DPP-4 inhibitors is associated with a lower risk of heart failure hospitalization, but not with a significant reduction in the risk of non-fatal myocardial infarction or stroke.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure

Phyo T. Htoo et al.

Summary: This study evaluated the relative cardiovascular effectiveness of SGLT2i and GLP-1RA in routine care populations with atherosclerotic cardiovascular diseases (CVDs) or heart failure (HF). The results showed that SGLT2i reduced the risk of hospitalized HF in patients with a history of HF but no CVD. However, GLP-1RA was associated with lower occurrence of atherosclerotic CVD events in patients without prior CVD or HF.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users

Jiandong Zhou et al.

Summary: This study compared the rates of major cardiovascular adverse events between users of sodium-glucose cotransporter-2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) in a Chinese population. The results showed that the use of SGLT2 inhibitors was associated with a significantly lower risk of new-onset heart failure, myocardial infarction, cardiovascular mortality, and all-cause mortality.

ESC HEART FAILURE (2022)

Add to Collection

Article Health Care Sciences & Services

Clinical Observation of SGLT2 Inhibitor Therapy for Cardiac Arrhythmia and Related Cardiovascular Disease in Diabetic Patients with Controlled Hypertension

Shih-Jie Jhuo et al.

Summary: This study demonstrated that treatment of type 2 diabetes mellitus patients with SGLT2 inhibitors could significantly reduce the incidence of total cardiac arrhythmia and atrial fibrillation, as well as decrease the risk of stroke, heart failure, and myocardial infarction. Additional investigations are needed to further confirm these findings.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Endocrinology & Metabolism

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan

Atsunori Kashiwagi et al.

Summary: In patients with type 2 diabetes mellitus without a history of cardiovascular disease, sodium-glucose cotransporter 2 inhibitors (SGLT2i) were associated with a significant reduction in hospitalization for heart failure (hHF) risk compared to dipeptidyl peptidase-4 inhibitors (DPP4i). SGLT2i was also associated with a significant risk reduction of all-cause death (ACD) and the composite of hHF or ACD events in the full cohort. Similar results were observed among patients with and without a history of cardiovascular disease.

JOURNAL OF DIABETES INVESTIGATION (2022)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review

Chun-Ting Yang et al.

Summary: Among Asian patients with type 2 diabetes (T2D), SGLT2 inhibitors (SGLT2is) showed benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4is) for multiple clinical outcomes. Further research is needed to explore the heterogeneous treatment effects of SGLT2is and DPP4is by race/ethnicity.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

Alison K. Wright et al.

Summary: The study suggests that SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF, while GLP-1RA appears to be beneficial for HF.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus

C. K. H. Wong et al.

Summary: The study showed that among type 2 diabetes patients, SGLT2i users had significant benefits in reducing the risk of cardiovascular diseases and potential benefits in lowering risks of end-stage renal diseases and all-cause mortality. Insulin users had higher risks of cardiovascular diseases compared to SGLT2i users.

DIABETES & METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism

Lower cardiorenal risk withsodium-glucosecotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

Kare I. Birkeland et al.

Summary: In patients with type 2 diabetes without prevalent cardiovascular and renal disease, the use of SGLT2i was associated with a lower risk of heart failure and chronic kidney disease compared to DPP4i. There were no significant differences in the risk of stroke and myocardial infarction between the two groups. This multinational observational study suggests that SGLT2i may have better clinical outcomes in patients with type 2 diabetes who are free from cardiovascular and renal disease.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Surgery

Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis

Roman N. Rodionov et al.

Summary: This study examined the association between HHF and LEA in patients with type 2 diabetes and PAD initiating SGLT2 inhibitors, before and after the EMA warning in 2017. The study found that PAD patients generally have higher amputation risks and that the differences in outcomes among study groups decreased after the EMA warning, indicating that regulatory surveillance measures were effective.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2021)

Add to Collection

Article Endocrinology & Metabolism

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study

Gabor Suto et al.

Summary: The study found that compared to DPP-4i, SGLT2i treatment is associated with lower all-cause mortality, hospitalization for heart failure, and risk of cancer, but with a higher risk of lower limb amputation. Additionally, adding SGLT2i to DPP-4i treatment can further decrease all-cause mortality.

BMJ OPEN DIABETES RESEARCH & CARE (2021)

Add to Collection

Article Endocrinology & Metabolism

Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts

Marta Baviera et al.

Summary: This observational cohort study in Italy compared the efficacy and safety of GLP-1RAs and SGLT2 inhibitors with other AHAs in large and unselected populations. The findings showed that GLP-1RAs and SGLT2 inhibitors were associated with lower rates of death, cardiovascular events, and heart failure compared to other AHAs, indicating their favorable effects in type 2 diabetes patients beyond those with cardiovascular disease.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry

Peter M. Becher et al.

Summary: In this study, the use of SGLT2i in HF patients with T2DM increased over time, particularly in those with specialist care, younger age, ischemic heart disease, and preserved renal function. SGLT2i use was associated with a 30% lower risk of cardiovascular death or first HF hospitalization, as well as lower risks of all-cause and CV death, HF and CV hospitalization, and CV death/myocardial infarction/stroke.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Review Pharmacology & Pharmacy

SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies

Annamaria Mascolo et al.

Summary: This study conducted a meta-analysis to evaluate the effects of SGLT2 inhibitors on cardiovascular and cerebrovascular outcomes in patients with T2DM. The results showed that SGLT2 inhibitors reduced the risk of stroke compared to DPP-4 inhibitors and non-SGLT2 inhibitors, and were also associated with decreased risk of cardiovascular outcomes and mortality in all comparisons.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Review Multidisciplinary Sciences

Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis

Chun-xing Li et al.

Summary: The study analyzed the real-world effect of SGLT-2i on cardiovascular outcomes in patients with T2DM. The results showed that SGLT-2i reduced the risk of MACE, ACM, HHF, MI, stroke, CVM, and HF, but not UA or AF. The drug does not increase the risk of severe hypoglycemia and lower limb amputation.

PLOS ONE (2021)

Add to Collection

Article Medicine, General & Internal

Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study

Ernesto Martin et al.

Summary: The study found that prescribing canagliflozin at discharge was associated with a lower risk of readmission for heart failure and a reduction in NT-proBNP concentration in patients with diabetes.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care

Iskandar Idris et al.

Summary: The study found that in patients with type 2 diabetes, sodium-glucose co-transporter-2 inhibitors (SGLT2is) were associated with significantly lower risk of all-cause mortality, cardiovascular death, and hospitalization for heart failure or chronic kidney disease compared to dipeptidyl peptidase-4 inhibitors (DPP4is).

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Review Endocrinology & Metabolism

The effect of sodium-glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies

Jesper Krogh et al.

Summary: This review systematically assessed the effects of SGLT-2 inhibitors on mortality and heart failure in RCTs and observational studies. Heterogeneity between study results for all-cause mortality and cardiovascular mortality was explained by study type, caution is needed when using observational studies to guide treatment of patients with type 2 diabetes.

DIABETIC MEDICINE (2021)

Add to Collection

Article

Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers

Clinical Diabetes (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Jordi Real et al.

Summary: Evidence from a retrospective cohort study in Catalonia, Spain, showed that new users of SGLT2 inhibitors had a lower risk of heart failure, all-cause death, and chronic kidney disease compared to users of other glucose-lowering drugs.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies

Enrico Longato et al.

Summary: The study demonstrated that patients with T2D who initiated SGLT2i under routine care had better cardiovascular outcomes and lower all-cause mortality compared to similar patients who initiated DPP4i.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

Add to Collection

Article Endocrinology & Metabolism

Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study

Christina E. DeRemer et al.

Summary: The study aimed to compare the cardiovascular benefits of using GLP-1RA and SGLT2i as add-on therapies to metformin in adults with T2D, with and without a history of cardiovascular complications. Results indicate that SGLT2i may provide greater cardioprotective benefits compared to GLP-1RA for secondary prevention in individuals with established cardiovascular diseases.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study

Spela Zerovnik et al.

Summary: The study showed that SGLT2i and GLP-1RA as add-on therapy can reduce cardiovascular morbidity and mortality in patients with type 2 diabetes compared with DPP-4i.

BMJ OPEN (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

Reimar W. Thomsen et al.

Summary: In this study comparing the clinical outcomes of empagliflozin and liraglutide in treating patients with type 2 diabetes, both drugs showed similar effects on expanded major adverse cardiac events and heart failure or all-cause death. However, empagliflozin initiators had a lower rate of first heart failure or loop-diuretic initiation compared to liraglutide initiators.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care

W. Hinton et al.

DIABETIC MEDICINE (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

Marco Castellana et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

David Thein et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor

Hsin-Fu Lee et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

Kristian B. Filion et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

Tien-Hsing Chen et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events A Systematic Review and Meta-analysis

Sean L. Zheng et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Review Pharmacology & Pharmacy

Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies

Awadhesh Kumar Singh et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Health Care Sciences & Services

How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies

Michael Andrew Barrowman et al.

BMC MEDICAL RESEARCH METHODOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study

Elisabetta Patorno et al.

CIRCULATION (2019)

Add to Collection

Article Medicine, General & Internal

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study

Bjorn Pasternak et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat

Martin Bodtker Mortensen et al.

JAMA CARDIOLOGY (2019)

Add to Collection

Article Endocrinology & Metabolism

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study

Anna Norhammar et al.

DIABETES OBESITY & METABOLISM (2019)

Add to Collection

Review Medicine, General & Internal

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Health Care Sciences & Services

Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes

Elizabeth M. Garry et al.

Journal of Managed Care & Specialty Pharmacy (2019)

Add to Collection

Article Psychiatry

How to perform a meta-analysis with R: a practical tutorial

Sara Balduzzi et al.

EVIDENCE-BASED MENTAL HEALTH (2019)

Add to Collection

Article Endocrinology & Metabolism

Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study

Stephane Pintat et al.

BMJ OPEN DIABETES RESEARCH & CARE (2019)

Add to Collection

Article Endocrinology & Metabolism

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Sook Jung Lee et al.

JOURNAL OF OBESITY & METABOLIC SYNDROME (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study

Young-Gun Kim et al.

CARDIOVASCULAR DIABETOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)

Patrick B. Ryan et al.

DIABETES OBESITY & METABOLISM (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL

Matthew A. Cavender et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study

Mikhail Kosiborod et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Elisabetta Patorno et al.

BMJ-BRITISH MEDICAL JOURNAL (2018)

Add to Collection

Article Medicine, General & Internal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Elisabetta Patorno et al.

BMJ-BRITISH MEDICAL JOURNAL (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)

Jacob A. Udell et al.

CIRCULATION (2018)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

DIABETES CARE (2018)

Add to Collection

Article Endocrinology & Metabolism

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?

Samy Suissa

DIABETES CARE (2018)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Mikhail Kosiborod et al.

CIRCULATION (2017)

Add to Collection

Review Medicine, General & Internal

Rayyan-a web and mobile app for systematic reviews

Mourad Ouzzani et al.

SYSTEMATIC REVIEWS (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Health Care Sciences & Services

Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments

Carson Ka-Lok Lo et al.

BMC MEDICAL RESEARCH METHODOLOGY (2014)

Add to Collection

Review Endocrinology & Metabolism

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

B. Haas et al.

NUTRITION & DIABETES (2014)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The possibility of unmeasured confounding variables in observational studies: a forgotten fact?

James Brian Byrd et al.

HEART (2011)

Add to Collection

Article Medicine, General & Internal

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.

Faiez Zannad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross-sectional study

Tetsuro Tsujimoto et al.

BMJ OPEN (2011)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Conducting Meta-Analyses in R with the metafor Package

Wolfgang Viechtbauer

JOURNAL OF STATISTICAL SOFTWARE (2010)

Add to Collection

Article Public, Environmental & Occupational Health

Immortal time bias in pharmacoepidemiology

Samy Suissa

AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis

Jeffrey S. Berger et al.

AMERICAN JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

The 'number needed to treat turns 20 - and continues to be used and misused

Finlay A. McAlister

CANADIAN MEDICAL ASSOCIATION JOURNAL (2008)

Add to Collection

Review Medicine, General & Internal

Primary prevention of cardiovascular diseases with statin therapy - A meta-analysis of randomized controlled trials

Paaladinesh Thavendiranathan et al.

ARCHIVES OF INTERNAL MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis

DSH Bell et al.

CURRENT MEDICAL RESEARCH AND OPINION (2006)

Add to Collection

Article Cardiac & Cardiovascular Systems

Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus

R Scognamiglio et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)

Add to Collection

Article Cardiac & Cardiovascular Systems

Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging

N Rajagopalan et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)

Add to Collection

Article Medicine, General & Internal

Meta-analysis of observational studies in epidemiology - A proposal for reporting

DF Stroup et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)

Add to Collection

Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies

Related references

Export Citation

Share Paper